Acute Effect of modeRate-intensity aerOBIc Exercise on Colon Cancer Cell Growth (AEROBIC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04057274|
Recruitment Status : Recruiting
First Posted : August 15, 2019
Last Update Posted : September 26, 2019
This study involves drawing blood samples from men before and after they perform 30-minutes of moderate-intensity aerobic exercise. The investigators will evaluate whether adding the exercise serum to colon cancer cells in a dish can reduce the growth of the cells compared to the resting serum.
Note: serum is the liquid part of the blood that carries hormones and metabolites around the body.
|Condition or disease||Intervention/treatment||Phase|
|Colon Adenocarcinoma Colon Cancer||Other: Exercise assessment||Not Applicable|
Regular exercise is associated with a reduced risk of developing colon cancer. However, the mechanisms underpinning the anti-cancer effect of exercise are not yet fully understood. A recent theory suggests that each time you exercise, the short-lasting spikes in circulating hormones can suppress the growth of cancer cells. Hence, every exercise bout could have a direct anti-cancer effect.
This study will recruit men with an increased of colon cancer and explore whether incubating colon cancer cells with serum collected after a bout of moderate-intensity aerobic exercise influences cell viability in vitro.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||15 participants|
|Intervention Model:||Crossover Assignment|
|Intervention Model Description:||This is a randomised, counterbalanced, crossover study whereby all participants will complete an exercise assessment and a resting assessment in a randomised order.|
|Masking:||None (Open Label)|
|Masking Description:||It is not possible to blind participants nor investigators. Investigators will be blind to allocation order until after the first blood sample is drawn.|
|Official Title:||Effect of a Single Bout of Moderate-intensity Aerobic Exercise on Colon Cancer Cell Growth in Vitro|
|Actual Study Start Date :||September 23, 2019|
|Estimated Primary Completion Date :||July 31, 2020|
|Estimated Study Completion Date :||July 31, 2020|
Experimental: Exercise assessment
The exercise condition will involve venous blood samples being drawn immediately before and after a single bout of moderate-intensity aerobic interval exercise.
Other: Exercise assessment
The moderate-intensity aerobic interval exercise will be performed on a cycle ergometer under the supervision of trained staff in an exercise science laboratory. Participants will perform a 5 to 10-minute warm-up that begins by pedalling against a light resistance (60 W) and progressively increases in resistance until a target heart rate of 50-60% heart rate reserve is achieved. Participants will then complete 6 x 5-minute bouts at 60% heart rate reserve whilst maintaining a cadence of 60 rev·min-1, separated by 2.5-minutes of pedalling against light resistance (60 W). The session will finish with a cool-down at light resistance (60 W) lasting 10-minutes.
No Intervention: Resting assessment
The resting condition will involve venous blood samples being drawn before and after 60 minutes of seated rest.
- Cell viability (%) [ Time Frame: 24 hours ]Viability of a human colon cancer cell line (LoVo) will be assessed via quantification of the fluorescent signal by the resazurin assay (Sigma-Aldrich, Dorset, UK). Cells will be seeded in culture medium containing 10% serum from individual participants and incubated for 24 hours. Fluorescence will then be measured using a microplate reader at an excitation of 560 nm and emission of 590 nm. Background fluorescence will be subtracted from each well and then values will be normalised to fluorescence of control cells grown in 10% fetal bovine serum instead of participant serum to give a percent viability.
- Concentration of epinephrine (pg/ml) [ Time Frame: Immediately before and immediately after the exercise and resting assessments ]Systemic concentration of epinephrine will be measured from serum
- Concentration of norepinephrine (pg/ml) [ Time Frame: Immediately before and immediately after the exercise and resting assessments ]Systemic concentration of norepinephrine will be measured from serum
- Concentration of Interleukin 6 (pg/ml) [ Time Frame: Immediately before and immediately after the exercise and resting assessments ]Systemic concentration of Interleukin 6 will be measured from serum
- Concentration of Tumour Necrosis Factor alpha (pg/ml) [ Time Frame: Immediately before and immediately after the exercise and resting assessments ]Systemic concentration of Tumour Necrosis Factor alpha will be measured from serum
- Concentration of Insulin (pmol/l) [ Time Frame: Immediately before and immediately after the exercise and resting assessments ]Systemic concentration of Insulin will be measured from serum
- Concentration of Insulin-like growth factor 1 (ng/ml) [ Time Frame: Immediately before and immediately after the exercise and resting assessments ]Systemic concentration of Insulin-like growth factor 1 will be measured from serum
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04057274
|Contact: Samuel T Orange, PhD||+44 (0)191 227 email@example.com|
|Contact: John M Saxton, PhD||+ 44 (0)191 227 firstname.lastname@example.org|
|York St John University Sports Park||Recruiting|
|York, North Yorkshire, United Kingdom, YO31 8FY|
|Contact: Alastair Jordan, PhD 01904 876125 email@example.com|
|Northumbria University City Campus||Recruiting|
|Newcastle Upon Tyne, United Kingdom, NE1 8SG|
|Contact: Samuel Orange, PhD 01912273056 firstname.lastname@example.org|
|Principal Investigator:||Samuel T Orange, PhD||Northumbria University|